Literature DB >> 10749582

Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan.

C Marchisone1, F Del Grosso, L Masiello, M Prat, L Santi, D M Noonan.   

Abstract

Metastasis is a sequence of events including proliferation, migration, adhesion, invasion and subsequent metastatic growth of tumour cells in distant organs. We previously showed that highly metastatic variants of murine melanoma cells express higher levels of the basement membrane proteoglycan perlecan than low or non metastatic variants and expression of an antisense perlecan can reduce metastatic potential. In contrast, antisense expression of perlecan in fibrosarcoma cells was reported to enhance tumorigenesis. To better understand the role of perlecan in angiogenesis we have transfected KS-IMM, an immortalized cell line derived from a human Kaposi s sarcoma, with an antisense perlecan construct and investigated the positive/negative role of perlecan in KS. KS-IMM cells were transfected with either empty vector (neo) or the antisense perlecan construct and clones were isolated. Immuno-blot analysis showed a reduction of perlecan levels in two (AP3 and AP4) isolated clones, in Northern blot analysis endogenous perlecan was undetectable in the AP3 and AP4 clones, while it was present in the neo control clones. AP clones had a reduced migration to HGF in Boyden chambers as compared to neo clones. Proliferation in low serum or serum-free conditions was strongly reduced in the AP clones as compared to the neo control cells. The neotransfected cells showed rapid proliferation in low serum supplemented with HGF and VEGF, while antisense transfected clones showed little response. Finally, AP-trasfected KS-IMM cells had significantly reduced migration to VEGF and HGF with respect to controls. In contrast, when the AP transfected cells were injected in nude mice they paradoxically showed enhanced tumor growth as compared to controls. Our preliminary data indicate that perlecan reduction plays a crucial role on Kaposi s sarcoma cell migration and proliferation in vitro. However, in vivo KS-IMM depleted of perlecan had a growth advantage. A possible hypothesis is that perlecan is necessary for growth of KS-IMM cells in vitro, however its down-regulation might promote angiogenesis through increased angiogenic growth factor diffusion, resulting in enhanced tumor growth in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749582     DOI: 10.1007/bf03032652

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  35 in total

1.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

2.  The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule.

Authors:  D M Noonan; A Fulle; P Valente; S Cai; E Horigan; M Sasaki; Y Yamada; J R Hassell
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

Review 3.  Proteoglycans: structures and interactions.

Authors:  L Kjellén; U Lindahl
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

4.  A human beta-actin expression vector system directs high-level accumulation of antisense transcripts.

Authors:  P Gunning; J Leavitt; G Muscat; S Y Ng; L Kedes
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

5.  A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells.

Authors:  M Mathiak; C Yenisey; D S Grant; B Sharma; R V Iozzo
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

Review 6.  A review of Kaposi's sarcoma.

Authors:  J Armes
Journal:  Adv Cancer Res       Date:  1989       Impact factor: 6.242

7.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

8.  Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors.

Authors:  S Tessler; P Rockwell; D Hicklin; T Cohen; B Z Levi; L Witte; I R Lemischka; G Neufeld
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

9.  Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1.

Authors:  M Mali; K Elenius; H M Miettinen; M Jalkanen
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

10.  Perlecan maintains the integrity of cartilage and some basement membranes.

Authors:  M Costell; E Gustafsson; A Aszódi; M Mörgelin; W Bloch; E Hunziker; K Addicks; R Timpl; R Fässler
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  12 in total

Review 1.  Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena.

Authors:  R V Iozzo; J D San Antonio
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Tumor attenuation by combined heparan sulfate and polyamine depletion.

Authors:  Mattias Belting; Lubor Borsig; Mark M Fuster; Jillian R Brown; Lo Persson; Lars-Ake Fransson; Jeffrey D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.

Authors:  Fengying Tang; Megan S Lord; William B Stallcup; John M Whitelock
Journal:  J Biochem       Date:  2018-05-01       Impact factor: 3.387

4.  Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo.

Authors:  Cristiana Savorè; Chu Zhang; Caroline Muir; Riting Liu; Jeffrey Wyrwa; Jun Shu; Haiyen E Zhau; Leland W K Chung; Daniel D Carson; Mary C Farach-Carson
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling.

Authors:  Malin Jansson; Ola Billing; Carl Herdenberg; Christina Lundin; Egle Tolockiene; Anoosheh Nazemroaya; Malin Sund
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-03-02       Impact factor: 2.673

Review 6.  Syndecan-4: dispensable or indispensable?

Authors:  Sarah A Wilcox-Adelman; Fabienne Denhez; Tokuro Iwabuchi; Stefania Saoncella; Enzo Calautti; Paul F Goetinck
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan.

Authors:  Jinming Yang; Ann Richmond
Journal:  Mol Ther       Date:  2004-06       Impact factor: 11.454

Review 9.  Extracellular Matrix, a Hard Player in Angiogenesis.

Authors:  Maurizio Mongiat; Eva Andreuzzi; Giulia Tarticchio; Alice Paulitti
Journal:  Int J Mol Sci       Date:  2016-11-01       Impact factor: 5.923

10.  KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

Authors:  István Kenessey; Krisztina Kói; Orsolya Horváth; Mihály Cserepes; Dávid Molnár; Vera Izsák; Judit Dobos; Balázs Hegedűs; József Tóvári; József Tímár
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.